The B-box domain and the PRY-SPRY domain of recombinant human MG53 are critical for its inhibitory effects on angiogenesis

Key Points

• Angiogenesis inhibition is significantly associated with the B-box and PRY-SPRY domains of recombinant human MG53, highlighting their functional importance.
• Key evidence shows that specific domains of MG53 lead to a substantial reduction in angiogenic activity, emphasizing their role in vascular biology.
• Assessment of the effects utilized recombinant human MG53 to explore its inhibitory mechanisms on angiogenesis through advanced biochemical assays.
• The findings highlight potential therapeutic applications targeting these domains, yet further research is needed to confirm their in vivo relevance.